skip navigation links
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 14.12e (Release date: 2014-12-29-08:00)
SearchBox Top
SearchBox Bottom
Icrucumab (Code C79808)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Icrucumab

Definition: A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1, which may prevent the activation of downstream signaling pathways and so inhibit tumor angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2 signaling.

Display Name: Icrucumab

Label: Icrucumab

NCI Thesaurus Code: C79808 (Search for linked caDSR metadata)

Synonyms & Abbreviations: (see Synonym Details)
Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody IMC-18F1
Anti-VEGFR-1 Monoclonal Antibody IMC-18F1

External Source Codes: 
CAS Registry Number 1024603-92-6 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 625428 (check for NCI PDQ closed clinical trial info)
PDQ Open Trial Search ID 625428 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703168

Other Properties:
code C79808
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-VEGFR-1_Monoclonal_Antibody_IMC-18F1
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom